Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial
() -- Anixa Biosciences (ANIX) said Monday the first patient has been treated in the fifth cohort of its phase 1 trial evaluating its novel CAR-T therapy lira-cel, which targets follicle stimulating hormone receptor for recurrent ovarian cancer. The trial is designed to assess safety, tolerability and preliminary signs